WEBVTT
Kind: captions
Language: en

00:00:00.410 --> 00:00:02.530 

produced<00:00:01.220> with<00:00:01.370> exclusive<00:00:01.910> support<00:00:02.270> from

00:00:02.530 --> 00:00:02.540 
produced with exclusive support from

00:00:02.540 --> 00:00:11.530 
produced with exclusive support from
Bavarian<00:00:03.080> Nordic<00:00:03.439> and<00:00:03.590> dendron<00:00:10.540> throughout

00:00:11.530 --> 00:00:11.540 
Bavarian Nordic and dendron throughout

00:00:11.540 --> 00:00:13.900 
Bavarian Nordic and dendron throughout
our<00:00:11.810> lives<00:00:12.020> the<00:00:12.380> cells<00:00:12.620> in<00:00:12.800> our<00:00:12.890> body<00:00:12.950> grow<00:00:13.580> and

00:00:13.900 --> 00:00:13.910 
our lives the cells in our body grow and

00:00:13.910 --> 00:00:16.960 
our lives the cells in our body grow and
divide<00:00:14.300> but<00:00:15.230> when<00:00:15.410> cells<00:00:15.710> start<00:00:16.160> dividing<00:00:16.340> and

00:00:16.960 --> 00:00:16.970 
divide but when cells start dividing and

00:00:16.970 --> 00:00:19.330 
divide but when cells start dividing and
spreading<00:00:17.480> uncontrollably<00:00:18.380> they<00:00:18.950> become

00:00:19.330 --> 00:00:19.340 
spreading uncontrollably they become

00:00:19.340 --> 00:00:22.300 
spreading uncontrollably they become
cancerous<00:00:20.050> there<00:00:21.050> are<00:00:21.200> more<00:00:21.350> than<00:00:21.500> 200

00:00:22.300 --> 00:00:22.310 
cancerous there are more than 200

00:00:22.310 --> 00:00:24.910 
cancerous there are more than 200
different<00:00:22.460> types<00:00:22.700> of<00:00:23.180> cancer<00:00:23.660> and<00:00:23.920> scientists

00:00:24.910 --> 00:00:24.920 
different types of cancer and scientists

00:00:24.920 --> 00:00:26.740 
different types of cancer and scientists
are<00:00:25.039> continually<00:00:25.730> developing<00:00:26.390> and<00:00:26.539> testing

00:00:26.740 --> 00:00:26.750 
are continually developing and testing

00:00:26.750 --> 00:00:30.609 
are continually developing and testing
new<00:00:27.170> ways<00:00:27.740> to<00:00:27.770> treat<00:00:28.280> them<00:00:29.110> most<00:00:30.110> cancer

00:00:30.609 --> 00:00:30.619 
new ways to treat them most cancer

00:00:30.619 --> 00:00:33.279 
new ways to treat them most cancer
therapies<00:00:31.070> involve<00:00:31.490> drugs<00:00:31.970> designed<00:00:32.539> to<00:00:32.989> kill

00:00:33.279 --> 00:00:33.289 
therapies involve drugs designed to kill

00:00:33.289 --> 00:00:36.069 
therapies involve drugs designed to kill
the<00:00:33.559> rapidly<00:00:33.890> dividing<00:00:34.370> cells<00:00:34.780> this<00:00:35.780> is<00:00:35.929> what

00:00:36.069 --> 00:00:36.079 
the rapidly dividing cells this is what

00:00:36.079 --> 00:00:39.040 
the rapidly dividing cells this is what
chemotherapy<00:00:37.039> does<00:00:37.749> but<00:00:38.749> there<00:00:38.899> is<00:00:39.019> a

00:00:39.040 --> 00:00:39.050 
chemotherapy does but there is a

00:00:39.050 --> 00:00:41.500 
chemotherapy does but there is a
different<00:00:39.530> approach<00:00:39.829> called<00:00:40.479> immunotherapy

00:00:41.500 --> 00:00:41.510 
different approach called immunotherapy

00:00:41.510 --> 00:00:44.410 
different approach called immunotherapy
immunotherapy<00:00:42.409> uses<00:00:43.339> the<00:00:43.489> body's<00:00:43.789> own<00:00:44.030> immune

00:00:44.410 --> 00:00:44.420 
immunotherapy uses the body's own immune

00:00:44.420 --> 00:00:47.680 
immunotherapy uses the body's own immune
system<00:00:44.749> to<00:00:45.260> fight<00:00:45.559> cancer<00:00:46.239> this<00:00:47.239> involves

00:00:47.680 --> 00:00:47.690 
system to fight cancer this involves

00:00:47.690 --> 00:00:50.200 
system to fight cancer this involves
activating<00:00:48.499> immune<00:00:48.800> cells<00:00:49.100> and<00:00:49.370> getting<00:00:50.059> them

00:00:50.200 --> 00:00:50.210 
activating immune cells and getting them

00:00:50.210 --> 00:00:51.969 
activating immune cells and getting them
to<00:00:50.239> recognize<00:00:50.780> the<00:00:50.809> cancer<00:00:51.469> tissue<00:00:51.649> as

00:00:51.969 --> 00:00:51.979 
to recognize the cancer tissue as

00:00:51.979 --> 00:00:55.299 
to recognize the cancer tissue as
different<00:00:52.760> from<00:00:52.819> normal<00:00:53.179> body<00:00:53.600> cells<00:00:54.309> this

00:00:55.299 --> 00:00:55.309 
different from normal body cells this

00:00:55.309 --> 00:00:58.000 
different from normal body cells this
isn't<00:00:55.729> easy<00:00:55.999> but<00:00:56.389> recently<00:00:57.229> the<00:00:57.499> field<00:00:57.769> has

00:00:58.000 --> 00:00:58.010 
isn't easy but recently the field has

00:00:58.010 --> 00:01:00.549 
isn't easy but recently the field has
had<00:00:58.190> some<00:00:58.429> success<00:00:58.839> the<00:00:59.839> FDA<00:01:00.229> has<00:01:00.530> approved

00:01:00.549 --> 00:01:00.559 
had some success the FDA has approved

00:01:00.559 --> 00:01:03.610 
had some success the FDA has approved
several<00:01:01.429> new<00:01:01.670> drugs<00:01:02.059> and<00:01:02.299> with<00:01:02.929> more<00:01:03.170> drugs<00:01:03.440> in

00:01:03.610 --> 00:01:03.620 
several new drugs and with more drugs in

00:01:03.620 --> 00:01:06.160 
several new drugs and with more drugs in
clinical<00:01:04.040> trials<00:01:04.519> some<00:01:05.180> say<00:01:05.420> we<00:01:05.689> are<00:01:05.810> entering

00:01:06.160 --> 00:01:06.170 
clinical trials some say we are entering

00:01:06.170 --> 00:01:09.240 
clinical trials some say we are entering
a<00:01:06.289> new<00:01:06.320> era<00:01:06.920> of<00:01:07.280> anti<00:01:07.729> cancer<00:01:07.939> immunotherapy

00:01:09.240 --> 00:01:09.250 
a new era of anti cancer immunotherapy

00:01:09.250 --> 00:01:12.249 
a new era of anti cancer immunotherapy
the<00:01:10.250> idea<00:01:10.670> goes<00:01:10.969> back<00:01:11.000> to<00:01:11.420> the<00:01:11.509> late<00:01:11.689> 19th

00:01:12.249 --> 00:01:12.259 
the idea goes back to the late 19th

00:01:12.259 --> 00:01:15.100 
the idea goes back to the late 19th
century<00:01:12.409> to<00:01:13.369> an<00:01:13.490> American<00:01:14.060> surgeon<00:01:14.360> named

00:01:15.100 --> 00:01:15.110 
century to an American surgeon named

00:01:15.110 --> 00:01:18.490 
century to an American surgeon named
William<00:01:15.619> Coley<00:01:16.130> he<00:01:17.000> injected<00:01:17.509> bacteria<00:01:18.259> into

00:01:18.490 --> 00:01:18.500 
William Coley he injected bacteria into

00:01:18.500 --> 00:01:21.550 
William Coley he injected bacteria into
tumors<00:01:18.950> and<00:01:19.399> watched<00:01:20.000> them<00:01:20.299> shrink<00:01:20.560> the

00:01:21.550 --> 00:01:21.560 
tumors and watched them shrink the

00:01:21.560 --> 00:01:23.950 
tumors and watched them shrink the
bacteria<00:01:22.189> it<00:01:22.430> seemed<00:01:22.759> were<00:01:23.299> provoking<00:01:23.659> an

00:01:23.950 --> 00:01:23.960 
bacteria it seemed were provoking an

00:01:23.960 --> 00:01:27.219 
bacteria it seemed were provoking an
immune<00:01:24.259> response<00:01:25.119> but<00:01:26.119> our<00:01:26.329> immune<00:01:26.630> system<00:01:27.079> is

00:01:27.219 --> 00:01:27.229 
immune response but our immune system is

00:01:27.229 --> 00:01:29.889 
immune response but our immune system is
highly<00:01:27.680> complex<00:01:28.130> and<00:01:28.369> for<00:01:28.909> most<00:01:29.149> of<00:01:29.359> the<00:01:29.479> 20th

00:01:29.889 --> 00:01:29.899 
highly complex and for most of the 20th

00:01:29.899 --> 00:01:32.410 
highly complex and for most of the 20th
century<00:01:30.409> scientists<00:01:31.250> struggled<00:01:31.850> to<00:01:32.240> turn

00:01:32.410 --> 00:01:32.420 
century scientists struggled to turn

00:01:32.420 --> 00:01:35.020 
century scientists struggled to turn
Coley's<00:01:32.990> observations<00:01:33.740> into<00:01:34.429> effective

00:01:35.020 --> 00:01:35.030 
Coley's observations into effective

00:01:35.030 --> 00:01:38.080 
Coley's observations into effective
cancer<00:01:35.359> treatments<00:01:36.079> but<00:01:37.039> after<00:01:37.429> decades<00:01:37.670> of

00:01:38.080 --> 00:01:38.090 
cancer treatments but after decades of

00:01:38.090 --> 00:01:39.719 
cancer treatments but after decades of
learning<00:01:38.509> about<00:01:38.689> the<00:01:38.899> immune<00:01:39.170> system<00:01:39.590> a

00:01:39.719 --> 00:01:39.729 
learning about the immune system a

00:01:39.729 --> 00:01:42.849 
learning about the immune system a
variety<00:01:40.729> of<00:01:40.780> immunotherapies<00:01:41.810> are<00:01:41.990> finally

00:01:42.849 --> 00:01:42.859 
variety of immunotherapies are finally

00:01:42.859 --> 00:01:46.090 
variety of immunotherapies are finally
making<00:01:43.039> their<00:01:43.369> way<00:01:43.549> to<00:01:43.609> the<00:01:43.880> clinic<00:01:44.920> we<00:01:45.920> can

00:01:46.090 --> 00:01:46.100 
making their way to the clinic we can

00:01:46.100 --> 00:01:49.080 
making their way to the clinic we can
divide<00:01:46.369> them<00:01:46.609> into<00:01:46.880> four<00:01:47.060> general<00:01:47.840> strategies

00:01:49.080 --> 00:01:49.090 
divide them into four general strategies

00:01:49.090 --> 00:01:52.389 
divide them into four general strategies
nonspecific<00:01:50.090> immune<00:01:50.479> stimulation<00:01:51.399> adoptive

00:01:52.389 --> 00:01:52.399 
nonspecific immune stimulation adoptive

00:01:52.399 --> 00:01:54.660 
nonspecific immune stimulation adoptive
cell<00:01:52.640> transfer<00:01:53.530> immune<00:01:54.530> checkpoint

00:01:54.660 --> 00:01:54.670 
cell transfer immune checkpoint

00:01:54.670 --> 00:02:00.099 
cell transfer immune checkpoint
blockades<00:01:55.670> and<00:01:56.560> vaccination<00:01:57.560> strategies<00:01:59.109> the

00:02:00.099 --> 00:02:00.109 
blockades and vaccination strategies the

00:02:00.109 --> 00:02:02.679 
blockades and vaccination strategies the
first<00:02:00.520> nonspecific<00:02:01.520> immune<00:02:01.819> stimulation<00:02:02.329> is

00:02:02.679 --> 00:02:02.689 
first nonspecific immune stimulation is

00:02:02.689 --> 00:02:05.230 
first nonspecific immune stimulation is
used<00:02:03.469> to<00:02:03.679> give<00:02:03.829> a<00:02:03.859> general<00:02:04.340> boost<00:02:04.700> to<00:02:05.119> the

00:02:05.230 --> 00:02:05.240 
used to give a general boost to the

00:02:05.240 --> 00:02:09.910 
used to give a general boost to the
immune<00:02:05.479> system<00:02:05.509> in<00:02:06.170> vivo<00:02:07.930> to<00:02:08.930> do<00:02:09.080> this<00:02:09.320> some<00:02:09.890> of

00:02:09.910 --> 00:02:09.920 
immune system in vivo to do this some of

00:02:09.920 --> 00:02:11.800 
immune system in vivo to do this some of
the<00:02:10.130> many<00:02:10.400> cells<00:02:10.729> that<00:02:10.940> make<00:02:11.150> up<00:02:11.180> the<00:02:11.570> immune

00:02:11.800 --> 00:02:11.810 
the many cells that make up the immune

00:02:11.810 --> 00:02:14.020 
the many cells that make up the immune
system<00:02:12.260> such<00:02:12.830> as<00:02:12.890> these<00:02:13.310> antigen

00:02:14.020 --> 00:02:14.030 
system such as these antigen

00:02:14.030 --> 00:02:17.340 
system such as these antigen
presenting<00:02:14.630> cells<00:02:14.930> need<00:02:15.709> to<00:02:15.860> be<00:02:15.980> activated

00:02:17.340 --> 00:02:17.350 
presenting cells need to be activated

00:02:17.350 --> 00:02:20.080 
presenting cells need to be activated
researchers<00:02:18.350> can<00:02:18.470> do<00:02:18.709> this<00:02:18.950> by<00:02:19.430> injecting

00:02:20.080 --> 00:02:20.090 
researchers can do this by injecting

00:02:20.090 --> 00:02:22.809 
researchers can do this by injecting
molecules<00:02:20.720> that<00:02:21.020> bind<00:02:21.230> to<00:02:21.530> receptors<00:02:22.190> in<00:02:22.400> the

00:02:22.809 --> 00:02:22.819 
molecules that bind to receptors in the

00:02:22.819 --> 00:02:26.350 
molecules that bind to receptors in the
cell<00:02:23.090> membrane<00:02:23.800> the<00:02:24.800> activated<00:02:25.430> cells<00:02:25.760> then

00:02:26.350 --> 00:02:26.360 
cell membrane the activated cells then

00:02:26.360 --> 00:02:29.199 
cell membrane the activated cells then
alert<00:02:26.660> other<00:02:26.930> immune<00:02:27.410> cells<00:02:27.709> such<00:02:28.400> as<00:02:28.430> these<00:02:28.790> T

00:02:29.199 --> 00:02:29.209 
alert other immune cells such as these T

00:02:29.209 --> 00:02:32.530 
alert other immune cells such as these T
cells<00:02:30.130> T<00:02:31.130> cells<00:02:31.160> are<00:02:31.700> the<00:02:31.819> main<00:02:32.030> players<00:02:32.390> in

00:02:32.530 --> 00:02:32.540 
cells T cells are the main players in

00:02:32.540 --> 00:02:35.320 
cells T cells are the main players in
the<00:02:32.750> fight<00:02:32.959> against<00:02:33.380> cancer<00:02:33.640> when<00:02:34.640> activated

00:02:35.320 --> 00:02:35.330 
the fight against cancer when activated

00:02:35.330 --> 00:02:42.080 
the fight against cancer when activated
they<00:02:35.810> can<00:02:35.989> attack<00:02:36.350> and<00:02:36.590> kill<00:02:37.040> tumor<00:02:37.489> cells

00:02:42.080 --> 00:02:42.090 

00:02:42.090 --> 00:02:45.350 

for<00:02:42.630> full<00:02:42.930> activation<00:02:43.440> small<00:02:44.370> cell<00:02:44.819> signaling

00:02:45.350 --> 00:02:45.360 
for full activation small cell signaling

00:02:45.360 --> 00:02:47.720 
for full activation small cell signaling
molecules<00:02:45.840> called<00:02:46.170> cytokines<00:02:47.010> are<00:02:47.370> needed

00:02:47.720 --> 00:02:47.730 
molecules called cytokines are needed

00:02:47.730 --> 00:02:51.220 
molecules called cytokines are needed
two<00:02:48.720> cytokines<00:02:49.580> interferon<00:02:50.580> alpha<00:02:50.790> and

00:02:51.220 --> 00:02:51.230 
two cytokines interferon alpha and

00:02:51.230 --> 00:02:54.110 
two cytokines interferon alpha and
interleukin<00:02:52.230> 2<00:02:52.590> have<00:02:53.280> been<00:02:53.459> developed<00:02:53.910> as

00:02:54.110 --> 00:02:54.120 
interleukin 2 have been developed as

00:02:54.120 --> 00:02:56.510 
interleukin 2 have been developed as
drugs<00:02:54.480> and<00:02:54.750> approved<00:02:55.349> for<00:02:55.620> use<00:02:55.800> against<00:02:56.190> some

00:02:56.510 --> 00:02:56.520 
drugs and approved for use against some

00:02:56.520 --> 00:02:59.259 
drugs and approved for use against some
forms<00:02:56.880> of<00:02:57.000> cancer<00:02:57.380> including<00:02:58.380> melanoma

00:02:59.259 --> 00:02:59.269 
forms of cancer including melanoma

00:02:59.269 --> 00:03:02.059 
forms of cancer including melanoma
another<00:03:00.269> way<00:03:00.450> to<00:03:00.510> stimulate<00:03:00.870> immune<00:03:01.530> cells<00:03:01.830> in

00:03:02.059 --> 00:03:02.069 
another way to stimulate immune cells in

00:03:02.069 --> 00:03:05.360 
another way to stimulate immune cells in
vivo<00:03:02.580> is<00:03:02.819> to<00:03:03.300> inject<00:03:03.690> bacteria<00:03:03.980> like<00:03:04.980> William

00:03:05.360 --> 00:03:05.370 
vivo is to inject bacteria like William

00:03:05.370 --> 00:03:07.699 
vivo is to inject bacteria like William
Coley<00:03:05.790> did<00:03:06.000> this<00:03:06.840> has<00:03:07.019> led<00:03:07.200> to<00:03:07.410> a<00:03:07.440> rather

00:03:07.699 --> 00:03:07.709 
Coley did this has led to a rather

00:03:07.709 --> 00:03:12.140 
Coley did this has led to a rather
surprising<00:03:08.069> use<00:03:08.760> of<00:03:09.000> the<00:03:09.209> BCG<00:03:09.870> vaccine<00:03:10.940> BCG<00:03:11.940> is

00:03:12.140 --> 00:03:12.150 
surprising use of the BCG vaccine BCG is

00:03:12.150 --> 00:03:14.150 
surprising use of the BCG vaccine BCG is
normally<00:03:12.569> given<00:03:12.720> to<00:03:12.870> children<00:03:13.530> as<00:03:13.680> protection

00:03:14.150 --> 00:03:14.160 
normally given to children as protection

00:03:14.160 --> 00:03:17.240 
normally given to children as protection
against<00:03:14.690> tuberculosis<00:03:15.690> but<00:03:16.560> scientists<00:03:17.069> have

00:03:17.240 --> 00:03:17.250 
against tuberculosis but scientists have

00:03:17.250 --> 00:03:19.460 
against tuberculosis but scientists have
found<00:03:17.519> that<00:03:17.700> the<00:03:17.910> weakened<00:03:18.390> bacteria<00:03:19.140> in<00:03:19.350> the

00:03:19.460 --> 00:03:19.470 
found that the weakened bacteria in the

00:03:19.470 --> 00:03:21.590 
found that the weakened bacteria in the
vaccine<00:03:19.920> can<00:03:20.459> also<00:03:20.640> help<00:03:20.970> patients<00:03:21.269> with

00:03:21.590 --> 00:03:21.600 
vaccine can also help patients with

00:03:21.600 --> 00:03:24.620 
vaccine can also help patients with
bladder<00:03:22.019> cancer<00:03:22.489> the<00:03:23.489> bacteria<00:03:24.090> appear<00:03:24.480> to

00:03:24.620 --> 00:03:24.630 
bladder cancer the bacteria appear to

00:03:24.630 --> 00:03:27.050 
bladder cancer the bacteria appear to
cause<00:03:24.840> inflammation<00:03:25.350> which<00:03:26.310> increases<00:03:26.940> the

00:03:27.050 --> 00:03:27.060 
cause inflammation which increases the

00:03:27.060 --> 00:03:29.150 
cause inflammation which increases the
number<00:03:27.330> of<00:03:27.360> immune<00:03:27.690> cells<00:03:28.049> around<00:03:28.470> the<00:03:28.709> cancer

00:03:29.150 --> 00:03:29.160 
number of immune cells around the cancer

00:03:29.160 --> 00:03:37.260 
number of immune cells around the cancer
helping<00:03:29.940> them<00:03:30.090> to<00:03:30.269> homed<00:03:30.480> in<00:03:30.660> on<00:03:30.720> their<00:03:31.049> target

00:03:37.260 --> 00:03:37.270 

00:03:37.270 --> 00:03:40.030 

nonspecific<00:03:38.270> immunity<00:03:39.080> can<00:03:39.560> also<00:03:39.739> be

00:03:40.030 --> 00:03:40.040 
nonspecific immunity can also be

00:03:40.040 --> 00:03:41.920 
nonspecific immunity can also be
achieved<00:03:40.130> by<00:03:40.580> removing<00:03:40.910> so-called

00:03:41.920 --> 00:03:41.930 
achieved by removing so-called

00:03:41.930 --> 00:03:45.130 
achieved by removing so-called
immune<00:03:42.380> checkpoint<00:03:42.580> blockades<00:03:44.140> these

00:03:45.130 --> 00:03:45.140 
immune checkpoint blockades these

00:03:45.140 --> 00:03:47.350 
immune checkpoint blockades these
blockades<00:03:45.620> normally<00:03:46.310> dampen<00:03:46.849> down<00:03:46.880> the

00:03:47.350 --> 00:03:47.360 
blockades normally dampen down the

00:03:47.360 --> 00:03:49.570 
blockades normally dampen down the
immune<00:03:47.630> response<00:03:47.660> to<00:03:48.530> prevent<00:03:48.920> collateral

00:03:49.570 --> 00:03:49.580 
immune response to prevent collateral

00:03:49.580 --> 00:03:52.270 
immune response to prevent collateral
damage<00:03:50.000> to<00:03:50.239> healthy<00:03:50.660> tissue<00:03:50.920> but<00:03:51.920> to<00:03:52.069> fight

00:03:52.270 --> 00:03:52.280 
damage to healthy tissue but to fight

00:03:52.280 --> 00:03:54.910 
damage to healthy tissue but to fight
cancer<00:03:52.819> scientists<00:03:53.630> need<00:03:53.959> to<00:03:54.140> remove<00:03:54.530> some<00:03:54.890> of

00:03:54.910 --> 00:03:54.920 
cancer scientists need to remove some of

00:03:54.920 --> 00:03:56.530 
cancer scientists need to remove some of
these<00:03:55.099> blockades<00:03:55.610> to<00:03:55.970> make<00:03:56.150> the<00:03:56.330> immune

00:03:56.530 --> 00:03:56.540 
these blockades to make the immune

00:03:56.540 --> 00:03:59.380 
these blockades to make the immune
response<00:03:56.800> stronger<00:03:57.940> the<00:03:58.940> antibody

00:03:59.380 --> 00:03:59.390 
response stronger the antibody

00:03:59.390 --> 00:04:01.809 
response stronger the antibody
ipilimumab<00:03:59.920> also<00:04:00.920> known<00:04:01.130> as<00:04:01.310> your<00:04:01.580> voi

00:04:01.809 --> 00:04:01.819 
ipilimumab also known as your voi

00:04:01.819 --> 00:04:04.320 
ipilimumab also known as your voi
targets<00:04:02.660> a<00:04:02.750> blockade<00:04:03.140> molecule<00:04:03.680> called

00:04:04.320 --> 00:04:04.330 
targets a blockade molecule called

00:04:04.330 --> 00:04:08.080 
targets a blockade molecule called
ctla-4<00:04:05.330> it<00:04:06.260> got<00:04:06.500> FDA<00:04:06.860> approval<00:04:07.489> for<00:04:07.519> patients

00:04:08.080 --> 00:04:08.090 
ctla-4 it got FDA approval for patients

00:04:08.090 --> 00:04:10.660 
ctla-4 it got FDA approval for patients
with<00:04:08.269> advanced<00:04:08.630> stage<00:04:09.049> melanoma<00:04:09.890> in<00:04:10.040> summer

00:04:10.660 --> 00:04:10.670 
with advanced stage melanoma in summer

00:04:10.670 --> 00:04:13.390 
with advanced stage melanoma in summer
2011<00:04:11.120> and<00:04:11.630> it's<00:04:12.049> being<00:04:12.260> tested<00:04:12.500> for<00:04:13.040> several

00:04:13.390 --> 00:04:13.400 
2011 and it's being tested for several

00:04:13.400 --> 00:04:17.080 
2011 and it's being tested for several
other<00:04:13.640> types<00:04:13.970> of<00:04:14.150> cancer<00:04:15.820> activating<00:04:16.820> immune

00:04:17.080 --> 00:04:17.090 
other types of cancer activating immune

00:04:17.090 --> 00:04:19.330 
other types of cancer activating immune
cells<00:04:17.359> inside<00:04:17.959> the<00:04:18.200> body<00:04:18.380> can<00:04:18.709> be<00:04:18.739> difficult

00:04:19.330 --> 00:04:19.340 
cells inside the body can be difficult

00:04:19.340 --> 00:04:22.180 
cells inside the body can be difficult
but<00:04:19.970> the<00:04:20.090> next<00:04:20.450> strategy<00:04:20.919> adoptive<00:04:21.919> cell

00:04:22.180 --> 00:04:22.190 
but the next strategy adoptive cell

00:04:22.190 --> 00:04:25.210 
but the next strategy adoptive cell
transfer<00:04:22.850> combat<00:04:23.780> this<00:04:24.050> by<00:04:24.350> extracting<00:04:24.889> the

00:04:25.210 --> 00:04:25.220 
transfer combat this by extracting the

00:04:25.220 --> 00:04:26.879 
transfer combat this by extracting the
immune<00:04:25.490> cells<00:04:25.729> from<00:04:26.060> the<00:04:26.210> patient<00:04:26.690> and

00:04:26.879 --> 00:04:26.889 
immune cells from the patient and

00:04:26.889 --> 00:04:29.920 
immune cells from the patient and
activating<00:04:27.889> them<00:04:28.040> outside<00:04:28.760> the<00:04:29.000> body<00:04:29.150> it

00:04:29.920 --> 00:04:29.930 
activating them outside the body it

00:04:29.930 --> 00:04:32.140 
activating them outside the body it
enables<00:04:30.590> researchers<00:04:30.770> to<00:04:31.280> specifically

00:04:32.140 --> 00:04:32.150 
enables researchers to specifically

00:04:32.150 --> 00:04:35.770 
enables researchers to specifically
target<00:04:32.840> the<00:04:32.870> cancer<00:04:33.410> tissue<00:04:34.150> one<00:04:35.150> approach<00:04:35.510> is

00:04:35.770 --> 00:04:35.780 
target the cancer tissue one approach is

00:04:35.780 --> 00:04:38.050 
target the cancer tissue one approach is
to<00:04:35.870> take<00:04:36.290> immune<00:04:36.650> cells<00:04:36.950> directly<00:04:37.310> from<00:04:37.850> the

00:04:38.050 --> 00:04:38.060 
to take immune cells directly from the

00:04:38.060 --> 00:04:40.900 
to take immune cells directly from the
tumor<00:04:38.510> it's<00:04:39.410> difficult<00:04:39.950> to<00:04:40.130> extract<00:04:40.520> enough

00:04:40.900 --> 00:04:40.910 
tumor it's difficult to extract enough

00:04:40.910 --> 00:04:43.390 
tumor it's difficult to extract enough
cells<00:04:41.240> but<00:04:41.930> the<00:04:42.080> advantage<00:04:42.740> is<00:04:42.950> that<00:04:43.010> the

00:04:43.390 --> 00:04:43.400 
cells but the advantage is that the

00:04:43.400 --> 00:04:45.010 
cells but the advantage is that the
cells<00:04:43.669> have<00:04:43.850> already<00:04:44.270> learned<00:04:44.600> to<00:04:44.750> recognize

00:04:45.010 --> 00:04:45.020 
cells have already learned to recognize

00:04:45.020 --> 00:04:48.880 
cells have already learned to recognize
the<00:04:45.650> tumor<00:04:46.780> taking<00:04:47.780> cells<00:04:48.020> from<00:04:48.260> the<00:04:48.410> blood<00:04:48.560> is

00:04:48.880 --> 00:04:48.890 
the tumor taking cells from the blood is

00:04:48.890 --> 00:04:51.310 
the tumor taking cells from the blood is
much<00:04:49.310> easier<00:04:49.789> but<00:04:50.390> then<00:04:50.570> you've<00:04:50.780> got<00:04:50.990> to<00:04:51.140> use

00:04:51.310 --> 00:04:51.320 
much easier but then you've got to use

00:04:51.320 --> 00:04:53.740 
much easier but then you've got to use
genetic<00:04:51.890> engineering<00:04:52.460> to<00:04:53.030> arm<00:04:53.240> them<00:04:53.510> with

00:04:53.740 --> 00:04:53.750 
genetic engineering to arm them with

00:04:53.750 --> 00:04:57.040 
genetic engineering to arm them with
tumor<00:04:54.289> specific<00:04:54.550> receptors<00:04:55.550> either<00:04:56.539> way

00:04:57.040 --> 00:04:57.050 
tumor specific receptors either way

00:04:57.050 --> 00:04:59.440 
tumor specific receptors either way
the<00:04:57.229> cells<00:04:57.470> are<00:04:57.650> activated<00:04:58.100> using<00:04:58.520> cytokines

00:04:59.440 --> 00:04:59.450 
the cells are activated using cytokines

00:04:59.450 --> 00:05:01.840 
the cells are activated using cytokines
and<00:04:59.720> then<00:05:00.289> multiplied<00:05:00.950> in<00:05:01.190> petri<00:05:01.669> dishes

00:05:01.840 --> 00:05:01.850 
and then multiplied in petri dishes

00:05:01.850 --> 00:05:04.570 
and then multiplied in petri dishes
before<00:05:02.479> being<00:05:02.870> reintroduced<00:05:03.440> to<00:05:04.010> the<00:05:04.100> patient

00:05:04.570 --> 00:05:04.580 
before being reintroduced to the patient

00:05:04.580 --> 00:05:06.219 
before being reintroduced to the patient
at<00:05:04.820> the<00:05:05.690> moment

00:05:06.219 --> 00:05:06.229 
at the moment

00:05:06.229 --> 00:05:09.580 
at the moment
this<00:05:06.470> approach<00:05:06.800> is<00:05:06.910> experimental<00:05:08.320> the<00:05:09.320> fourth

00:05:09.580 --> 00:05:09.590 
this approach is experimental the fourth

00:05:09.590 --> 00:05:11.820 
this approach is experimental the fourth
strategy<00:05:09.950> uses<00:05:10.669> vaccinations

00:05:11.820 --> 00:05:11.830 
strategy uses vaccinations

00:05:11.830 --> 00:05:14.860 
strategy uses vaccinations
unlike<00:05:12.830> the<00:05:13.010> BCG<00:05:13.669> vaccine<00:05:14.120> that<00:05:14.330> we<00:05:14.450> mentioned

00:05:14.860 --> 00:05:14.870 
unlike the BCG vaccine that we mentioned

00:05:14.870 --> 00:05:16.690 
unlike the BCG vaccine that we mentioned
earlier<00:05:14.990> and<00:05:15.410> which<00:05:15.800> targets<00:05:16.310> the<00:05:16.460> immune

00:05:16.690 --> 00:05:16.700 
earlier and which targets the immune

00:05:16.700 --> 00:05:19.659 
earlier and which targets the immune
system<00:05:17.120> in<00:05:17.270> a<00:05:17.419> general<00:05:17.930> way<00:05:18.070> these<00:05:19.070> vaccines

00:05:19.659 --> 00:05:19.669 
system in a general way these vaccines

00:05:19.669 --> 00:05:22.120 
system in a general way these vaccines
are<00:05:19.970> used<00:05:20.270> to<00:05:20.479> direct<00:05:20.960> immune<00:05:21.380> cells<00:05:21.680> very

00:05:22.120 --> 00:05:22.130 
are used to direct immune cells very

00:05:22.130 --> 00:05:24.930 
are used to direct immune cells very
specifically<00:05:23.120> to<00:05:23.360> the<00:05:23.479> cancer<00:05:23.900> tissue

00:05:24.930 --> 00:05:24.940 
specifically to the cancer tissue

00:05:24.940 --> 00:05:27.490 
specifically to the cancer tissue
several<00:05:25.940> viral<00:05:26.419> vaccines<00:05:26.990> have<00:05:27.289> shown

00:05:27.490 --> 00:05:27.500 
several viral vaccines have shown

00:05:27.500 --> 00:05:30.460 
several viral vaccines have shown
promising<00:05:28.010> results<00:05:28.520> in<00:05:28.700> clinical<00:05:28.880> trials<00:05:29.660> for

00:05:30.460 --> 00:05:30.470 
promising results in clinical trials for

00:05:30.470 --> 00:05:32.770 
promising results in clinical trials for
example<00:05:30.979> a<00:05:31.100> weakened<00:05:31.639> version<00:05:31.700> of<00:05:32.210> the<00:05:32.330> herpes

00:05:32.770 --> 00:05:32.780 
example a weakened version of the herpes

00:05:32.780 --> 00:05:35.379 
example a weakened version of the herpes
simplex<00:05:33.200> virus<00:05:33.669> modified<00:05:34.669> to<00:05:34.850> produce<00:05:35.030> an

00:05:35.379 --> 00:05:35.389 
simplex virus modified to produce an

00:05:35.389 --> 00:05:37.659 
simplex virus modified to produce an
immune<00:05:35.690> stimulating<00:05:36.289> factor<00:05:36.889> is<00:05:37.039> being

00:05:37.659 --> 00:05:37.669 
immune stimulating factor is being

00:05:37.669 --> 00:05:39.909 
immune stimulating factor is being
developed<00:05:38.000> for<00:05:38.270> melanoma<00:05:38.840> and<00:05:39.229> head<00:05:39.560> and<00:05:39.710> neck

00:05:39.909 --> 00:05:39.919 
developed for melanoma and head and neck

00:05:39.919 --> 00:05:43.330 
developed for melanoma and head and neck
cancer<00:05:40.720> it's<00:05:41.720> also<00:05:42.080> possible<00:05:42.440> to<00:05:42.710> vaccinate

00:05:43.330 --> 00:05:43.340 
cancer it's also possible to vaccinate

00:05:43.340 --> 00:05:46.570 
cancer it's also possible to vaccinate
with<00:05:43.580> a<00:05:43.610> patient's<00:05:44.180> own<00:05:44.360> tumor<00:05:45.110> cells<00:05:45.580> some

00:05:46.570 --> 00:05:46.580 
with a patient's own tumor cells some

00:05:46.580 --> 00:05:49.540 
with a patient's own tumor cells some
cells<00:05:46.849> are<00:05:47.090> extracted<00:05:48.130> irradiated<00:05:49.130> to<00:05:49.340> stop

00:05:49.540 --> 00:05:49.550 
cells are extracted irradiated to stop

00:05:49.550 --> 00:05:50.379 
cells are extracted irradiated to stop
them<00:05:49.760> from<00:05:49.849> spread

00:05:50.379 --> 00:05:50.389 
them from spread

00:05:50.389 --> 00:05:52.149 
them from spread
and<00:05:50.569> then<00:05:50.960> engineered<00:05:51.650> to<00:05:51.889> secrete

00:05:52.149 --> 00:05:52.159 
and then engineered to secrete

00:05:52.159 --> 00:05:55.270 
and then engineered to secrete
activating<00:05:53.120> growth<00:05:53.449> factors<00:05:54.050> when<00:05:54.919> the<00:05:55.039> cells

00:05:55.270 --> 00:05:55.280 
activating growth factors when the cells

00:05:55.280 --> 00:05:57.520 
activating growth factors when the cells
are<00:05:55.400> injected<00:05:55.970> back<00:05:56.150> into<00:05:56.210> the<00:05:56.539> patient<00:05:56.990> the

00:05:57.520 --> 00:05:57.530 
are injected back into the patient the

00:05:57.530 --> 00:05:59.709 
are injected back into the patient the
growth<00:05:57.770> factors<00:05:58.250> alert<00:05:58.669> the<00:05:58.939> immune<00:05:59.240> system

00:05:59.709 --> 00:05:59.719 
growth factors alert the immune system

00:05:59.719 --> 00:06:02.800 
growth factors alert the immune system
to<00:05:59.750> the<00:06:00.080> cancer<00:06:00.610> but<00:06:01.610> it's<00:06:01.849> also<00:06:02.090> possible<00:06:02.509> to

00:06:02.800 --> 00:06:02.810 
to the cancer but it's also possible to

00:06:02.810 --> 00:06:04.390 
to the cancer but it's also possible to
vaccinate<00:06:03.469> with<00:06:03.620> a<00:06:03.650> person's<00:06:04.159> own<00:06:04.340> immune

00:06:04.390 --> 00:06:04.400 
vaccinate with a person's own immune

00:06:04.400 --> 00:06:07.899 
vaccinate with a person's own immune
cells<00:06:05.270> for<00:06:06.259> example<00:06:06.669> antigen<00:06:07.669> presenting

00:06:07.899 --> 00:06:07.909 
cells for example antigen presenting

00:06:07.909 --> 00:06:10.990 
cells for example antigen presenting
cells<00:06:08.509> can<00:06:08.810> be<00:06:08.930> taken<00:06:09.319> from<00:06:09.500> patients<00:06:10.069> matured

00:06:10.990 --> 00:06:11.000 
cells can be taken from patients matured

00:06:11.000 --> 00:06:13.540 
cells can be taken from patients matured
outside<00:06:11.599> the<00:06:11.750> body<00:06:11.900> and<00:06:12.139> loaded<00:06:12.919> with<00:06:13.099> tumor

00:06:13.540 --> 00:06:13.550 
outside the body and loaded with tumor

00:06:13.550 --> 00:06:16.420 
outside the body and loaded with tumor
antigen<00:06:14.150> when<00:06:15.139> the<00:06:15.289> cells<00:06:15.530> are<00:06:15.740> reintroduced

00:06:16.420 --> 00:06:16.430 
antigen when the cells are reintroduced

00:06:16.430 --> 00:06:18.820 
antigen when the cells are reintroduced
to<00:06:16.580> the<00:06:16.669> patient<00:06:17.210> the<00:06:17.750> antigen<00:06:18.259> stimulates

00:06:18.820 --> 00:06:18.830 
to the patient the antigen stimulates

00:06:18.830 --> 00:06:20.740 
to the patient the antigen stimulates
other<00:06:19.069> immune<00:06:19.460> cells<00:06:19.789> and<00:06:20.090> helps<00:06:20.389> them<00:06:20.539> to

00:06:20.740 --> 00:06:20.750 
other immune cells and helps them to

00:06:20.750 --> 00:06:24.399 
other immune cells and helps them to
recognize<00:06:21.229> the<00:06:21.500> tumor<00:06:22.419> the<00:06:23.419> first<00:06:23.690> vaccine<00:06:24.229> of

00:06:24.399 --> 00:06:24.409 
recognize the tumor the first vaccine of

00:06:24.409 --> 00:06:27.369 
recognize the tumor the first vaccine of
this<00:06:24.560> type<00:06:24.800> received<00:06:25.520> FDA<00:06:25.819> approval<00:06:26.060> in<00:06:26.719> 2010

00:06:27.369 --> 00:06:27.379 
this type received FDA approval in 2010

00:06:27.379 --> 00:06:29.200 
this type received FDA approval in 2010
for<00:06:27.650> the<00:06:27.740> treatment<00:06:28.219> of<00:06:28.370> some<00:06:28.669> prostate

00:06:29.200 --> 00:06:29.210 
for the treatment of some prostate

00:06:29.210 --> 00:06:31.869 
for the treatment of some prostate
cancers<00:06:29.560> it's<00:06:30.560> known<00:06:30.830> as<00:06:31.009> Provenge<00:06:31.550> or

00:06:31.869 --> 00:06:31.879 
cancers it's known as Provenge or

00:06:31.879 --> 00:06:35.080 
cancers it's known as Provenge or
syphilis<00:06:32.180> LT<00:06:33.159> the<00:06:34.159> other<00:06:34.400> vaccination

00:06:35.080 --> 00:06:35.090 
syphilis LT the other vaccination

00:06:35.090 --> 00:06:38.170 
syphilis LT the other vaccination
approaches<00:06:35.659> are<00:06:35.900> still<00:06:36.169> experimental<00:06:37.180> the

00:06:38.170 --> 00:06:38.180 
approaches are still experimental the

00:06:38.180 --> 00:06:40.420 
approaches are still experimental the
last<00:06:38.389> few<00:06:38.719> years<00:06:38.750> have<00:06:39.259> seen<00:06:39.289> many<00:06:39.770> promising

00:06:40.420 --> 00:06:40.430 
last few years have seen many promising

00:06:40.430 --> 00:06:42.070 
last few years have seen many promising
developments<00:06:41.180> in<00:06:41.360> anti-cancer

00:06:42.070 --> 00:06:42.080 
developments in anti-cancer

00:06:42.080 --> 00:06:44.469 
developments in anti-cancer
immunotherapies<00:06:43.009> but<00:06:43.729> there's<00:06:43.909> still<00:06:44.210> much

00:06:44.469 --> 00:06:44.479 
immunotherapies but there's still much

00:06:44.479 --> 00:06:47.230 
immunotherapies but there's still much
work<00:06:44.509> to<00:06:44.990> do<00:06:45.169> to<00:06:46.069> help<00:06:46.190> get<00:06:46.460> drugs<00:06:46.490> from<00:06:47.090> the

00:06:47.230 --> 00:06:47.240 
work to do to help get drugs from the

00:06:47.240 --> 00:06:49.600 
work to do to help get drugs from the
bench<00:06:47.479> through<00:06:48.139> clinical<00:06:48.650> trials<00:06:49.039> and<00:06:49.219> to<00:06:49.520> the

00:06:49.600 --> 00:06:49.610 
bench through clinical trials and to the

00:06:49.610 --> 00:06:52.119 
bench through clinical trials and to the
bedside<00:06:50.229> scientists<00:06:51.229> need<00:06:51.409> to<00:06:51.620> find<00:06:51.830> better

00:06:52.119 --> 00:06:52.129 
bedside scientists need to find better

00:06:52.129 --> 00:06:53.950 
bedside scientists need to find better
ways<00:06:52.400> to<00:06:52.789> judge<00:06:53.029> the<00:06:53.240> success<00:06:53.779> of

00:06:53.950 --> 00:06:53.960 
ways to judge the success of

00:06:53.960 --> 00:06:56.769 
ways to judge the success of
immunotherapies<00:06:54.889> in<00:06:55.159> patients<00:06:55.819> and<00:06:55.969> to<00:06:56.599> work

00:06:56.769 --> 00:06:56.779 
immunotherapies in patients and to work

00:06:56.779 --> 00:06:59.649 
immunotherapies in patients and to work
out<00:06:57.020> the<00:06:57.229> best<00:06:57.379> dose<00:06:58.060> right<00:06:59.060> now<00:06:59.330> it's

00:06:59.649 --> 00:06:59.659 
out the best dose right now it's

00:06:59.659 --> 00:07:01.779 
out the best dose right now it's
difficult<00:07:00.229> to<00:07:00.409> predict<00:07:00.770> who<00:07:01.009> might<00:07:01.219> respond

00:07:01.779 --> 00:07:01.789 
difficult to predict who might respond

00:07:01.789 --> 00:07:04.240 
difficult to predict who might respond
to<00:07:02.060> a<00:07:02.090> particular<00:07:02.330> treatment<00:07:03.050> and<00:07:03.500> some

00:07:04.240 --> 00:07:04.250 
to a particular treatment and some

00:07:04.250 --> 00:07:06.490 
to a particular treatment and some
responses<00:07:04.909> are<00:07:05.120> only<00:07:05.330> short-lived

00:07:06.490 --> 00:07:06.500 
responses are only short-lived

00:07:06.500 --> 00:07:09.279 
responses are only short-lived
if<00:07:06.589> these<00:07:07.400> hurdles<00:07:07.729> can<00:07:08.120> be<00:07:08.240> overcome<00:07:08.539> then

00:07:09.279 --> 00:07:09.289 
if these hurdles can be overcome then

00:07:09.289 --> 00:07:11.800 
if these hurdles can be overcome then
many<00:07:09.680> more<00:07:09.919> cancer<00:07:10.430> patients<00:07:10.969> could<00:07:11.270> benefit

00:07:11.800 --> 00:07:11.810 
many more cancer patients could benefit

00:07:11.810 --> 00:07:13.990 
many more cancer patients could benefit
from<00:07:12.020> strategies<00:07:12.949> that<00:07:13.279> boost<00:07:13.610> their<00:07:13.969> immune

00:07:13.990 --> 00:07:14.000 
from strategies that boost their immune

00:07:14.000 --> 00:07:24.360 
from strategies that boost their immune
system

00:07:24.360 --> 00:07:24.370 

00:07:24.370 --> 00:07:26.710 

produced<00:07:25.370> with<00:07:25.520> exclusive<00:07:26.090> support<00:07:26.420> from

00:07:26.710 --> 00:07:26.720 
produced with exclusive support from

00:07:26.720 --> 00:07:30.490 
produced with exclusive support from
Bavarian<00:07:27.230> Nordic<00:07:27.620> and<00:07:27.770> dendron

